Skip to content

LivaNova LIVN Additional Paid-In Capital

Additional Paid-In Capital at other companies

Haemonetics logo
HaemoneticsHAE
$554.14M+5.9%
Medtronic logo
MedtronicMDT
$20.93B+0.4%
ITG
Integer HoldingsITGR
$755.87M+0.2%
ResMed logo
ResMedRMD
$2.13B+7.2%
Novanta logo
NovantaNOVT
$556.41M+609%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$264.88M+27.1%

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's additional paid-in capital?
LivaNova (LIVN) reported additional paid-in capital of $2.25B in Q1 2026.
How has LivaNova's additional paid-in capital changed year-over-year?
LivaNova's additional paid-in capital increased by 1.4% year-over-year, from $2.22B to $2.25B.
What is the long-term trend for LivaNova's additional paid-in capital?
Over 5 years (2020 to 2025), LivaNova's additional paid-in capital has grown at a 5.0% compound annual growth rate (CAGR), from $1.77B to $2.25B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.